Food and Drug Administration Johnson & Johnson

FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

ConsumerAffairs · 2d

FDA approves nasal spray drug to treat depression

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monoth

Benzinga.com · 2d

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.

NJBIZ1d

J&J’s ketamine-based drug approved as standalone treatment

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

10d

Johnson & Johnson strikes $14.6bn deal for neuroscience biotech Intra-Cellular

Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical ...

IFLScience5h

FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

1don MSN

Trump administration directs federal health agencies to pause communications

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...

BioPharma Dive10d

J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Trump administration pauses communication from CDC, other health agencies

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results